Form 4: Supernus Executive Exercises Options, Sells Shares

A Supernus Pharmaceuticals executive exercised stock options and subsequently sold 5,000 shares of common stock for a profit.

Summary

• Frank Mottola, SVP, Chief Technology Operations Officer of Supernus Pharmaceuticals, Inc. (SUPN), engaged in an insider transaction on September 12, 2025.
• Mottola exercised 5,000 employee stock options at a price of $39.40 per share.
• Immediately following the exercise, Mottola sold 5,000 shares of common stock at a weighted average price of $45.87 per share.
• The sale price ranged from $45.73 to $45.96 per share.
• After these transactions, Mottola directly beneficially owns 15,496 shares of common stock and 5,000 employee stock options.
• The transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 6

Explanation: The filing details a routine, pre-planned insider transaction where an executive exercised options and sold shares for a profit. This is generally neutral for the company's stock outlook, as it's a personal financial event rather than a signal of company performance or strategic shift.

Positives

• The executive realized a profit from exercising stock options and selling the shares, indicating a successful personal investment outcome.
• The transaction was conducted under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not based on immediate, non-public information.

Negatives

• The sale of shares by an executive, even if pre-planned, can sometimes be viewed with caution by investors, as it reduces insider ownership.

Stakeholder Impact

• Shareholders may note the reduction in direct insider ownership, although the pre-planned nature of the transaction mitigates potential negative interpretations.

Key Dates

Recommendation

The filing details a routine, pre-planned insider transaction involving the exercise of stock options and subsequent sale of shares. This type of transaction, while showing an executive profiting, does not typically indicate a significant change in the company's fundamental outlook or warrant a strong investment action based solely on this report. Investors should consider broader company fundamentals and market conditions.

Keywords

Supernus Pharmaceuticals, SUPN, Form 4, insider transaction, stock option exercise, share sale, executive compensation, Rule 10b5-1